Compare LYEL & PFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYEL | PFN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.5M | 699.5M |
| IPO Year | 2021 | N/A |
| Metric | LYEL | PFN |
|---|---|---|
| Price | $23.39 | $7.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 133.6K | ★ 331.7K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.65 | $5.94 |
| 52 Week High | $45.00 | $7.58 |
| Indicator | LYEL | PFN |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 47.64 |
| Support Level | $22.75 | $7.41 |
| Resistance Level | $25.12 | $7.54 |
| Average True Range (ATR) | 2.58 | 0.07 |
| MACD | -1.30 | -0.00 |
| Stochastic Oscillator | 3.85 | 2.78 |
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.